What is Spirair?
Spirair operates at the intersection of clinical innovation and patient-centric design. Founded by Stanford Biodesign and Innovation fellows, the company is dedicated to addressing the persistent gaps in ENT care. By focusing on minimally invasive surgical solutions, Spirair aims to provide practitioners with tools that seamlessly integrate into existing treatment algorithms. The company's core value proposition lies in its commitment to improving respiratory health outcomes while simultaneously enhancing the overall patient experience, positioning itself as a critical player in the evolving landscape of specialized surgical instrumentation.
How much funding has Spirair raised?
Spirair has raised a total of $12.8M across 1 funding round:
Stock/Share Issuance
$12.8M
Stock/Share Issuance (2025): $12.8M, investors not publicly disclosed
Key Investors in Spirair
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Spirair?
Following this major strategic investment, Spirair is well-positioned to accelerate its research and development pipeline and expand its commercial footprint. The company is expected to leverage this capital to refine its minimally invasive platforms, ensuring that ENT specialists have access to high-efficacy tools that drive superior clinical results. As the firm transitions into its next phase of growth, the focus will likely shift toward scaling manufacturing capabilities and broadening market penetration, ultimately aiming to set a new standard for patient care in the ENT field.
See full Spirair company page
